Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen
暂无分享,去创建一个
[1] M. Gleave,et al. Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] H. Miyake,et al. 544 Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension , 2012 .
[3] M. Gleave,et al. Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c , 2011, Clinical Cancer Research.
[4] S. Ekici,et al. Clusterin Immunoreactivity as a Predictive Factor for Progression of Non-Muscle-Invasive Bladder Carcinoma , 2010, Urologia Internationalis.
[5] I. Tannock,et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Tenniswood,et al. Effects of clusterin over-expression on metastatic progression and therapy in breast cancer , 2010, BMC Cancer.
[7] O. Elashry,et al. Clusterin as a Diagnostic and Prognostic Marker for Transitional Cell Carcinoma of the Bladder , 2010, Pathology & Oncology Research.
[8] M. Gleave,et al. Clusterin Facilitates COMMD1 and I-κB Degradation to Enhance NF-κB Activity in Prostate Cancer Cells , 2010, Molecular Cancer Research.
[9] D. Xie,et al. Overexpression of Clusterin in Ovarian Cancer is Correlated With Impaired Survival , 2009, International Journal of Gynecologic Cancer.
[10] T. Xue,et al. Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer , 2009, International journal of cancer.
[11] M. Gleave,et al. Chemosensitization of gemcitabine‐resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti‐apoptotic gene, clusterin , 2009, BJU international.
[12] L. Margaritis,et al. Intracellular Clusterin Inhibits Mitochondrial Apoptosis by Suppressing p53-Activating Stress Signals and Stabilizing the Cytosolic Ku70-Bax Protein Complex , 2009, Clinical Cancer Research.
[13] M. Gleave,et al. Clusterin knockdown using the antisense oligonucleotide OGX‐011 re‐sensitizes docetaxel‐refractory prostate cancer PC‐3 cells to chemotherapy , 2008, BJU international.
[14] J. Closset,et al. Clusterin Activates Survival through the Phosphatidylinositol 3-Kinase/Akt Pathway* , 2008, Journal of Biological Chemistry.
[15] J. Jeon,et al. Clusterin, a novel modulator of TGF-β signaling, is involved in Smad2/3 stability , 2008 .
[16] M. Gleave,et al. A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer , 2008, Clinical Cancer Research.
[17] C. Dobson,et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[18] D. Michel,et al. Stress‐Induced Retrotranslocation of Clusterin/ApoJ into the Cytosol , 2007, Traffic.
[19] C. Tangen,et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. , 2006, Journal of the National Cancer Institute.
[20] D. Michel,et al. Up-regulation of the clusterin gene after proteotoxic stress: implication of HSF1-HSF2 heterocomplexes. , 2006, The Biochemical journal.
[21] M. Gleave,et al. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo , 2005, Molecular Cancer Therapeutics.
[22] M. Gleave,et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. , 2005, Journal of the National Cancer Institute.
[23] R. Taichman,et al. Clusterin inhibits apoptosis by interacting with activated Bax , 2005, Nature Cell Biology.
[24] H. Pehamberger,et al. Clusterin regulates drug-resistance in melanoma cells. , 2005, The Journal of investigative dermatology.
[25] M. Gleave,et al. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. , 2004, Molecular cancer therapeutics.
[26] G. Hart,et al. Glycobiology and Cancer: Meeting Summary and Future Directions , 2004, Cancer biology & therapy.
[27] P. Kantoff,et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Gleave,et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] M. Gleave,et al. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy , 2002, The Prostate.
[30] H. Miyake,et al. Over expression of clusterin is an independent prognostic factor for nonpapillary renal cell carcinoma. , 2002, The Journal of urology.
[31] H. Miyake,et al. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] M. Gleave,et al. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry. , 2001, The Journal of pharmacology and experimental therapeutics.
[33] H. Miyake,et al. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. , 2000, Cancer research.
[34] S Senn,et al. Repeated measures in clinical trials: simple strategies for analysis using summary measures. , 2000, Statistics in medicine.
[35] M. Gleave,et al. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. , 2000, Journal of the National Cancer Institute.
[36] J. Carver,et al. Clusterin Has Chaperone-like Activity Similar to That of Small Heat Shock Proteins* , 1999, The Journal of Biological Chemistry.
[37] George E. P. Box,et al. Empirical Model‐Building and Response Surfaces , 1988 .
[38] J R Anderson,et al. Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] J. Jeon,et al. Clusterin, a novel modulator of TGF-beta signaling, is involved in Smad2/3 stability. , 2008, Biochemical and biophysical research communications.
[40] M. Gleave,et al. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. , 2001, Neoplasia.
[41] H. Miyake,et al. Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cells. , 2001, Molecular urology.
[42] H. Miyake,et al. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. , 2000, Cancer research.